Données génétiques de la schizophrénie - Psychologie - M. Fouchey

37-285-A-16 Données génétiques de la schizophrénie
[2] D’Amato T. Épidémiologie génétique. In: Thibaut F, editor. Génétique
de la schizophrénie. Paris: John Libbey Eurotext; 2003. p. 29-54.
[3] Gottesman I, Shields J. Schizophrenia: the epigenetic puzzle.
Cambridge: Cambridge University Press; 1982.
[4] Maier W, Lichtermann D, Franke P, Heun R, Falkai P, Rietschel M. The
dichotomy of schizophrenia and affective disorders in extended
pedigrees. Schizophr Res 2002;57:259-66.
[5] Malaspina D. Paternal factors and schizophrenia risk: de novo mutations
and imprinting. Schizophr Bull 2001;27:379-93.
[6] Gershon ES, Cloninger RC. Genetic approaches to mental disorders.
Washington DC: American Psychiatric Press; 1994.
[7] Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P,
et al.Aroad map for efficient and reliable human genome epidemiology.
Nat Genet 2006;38:3-5.
[8] Delisi LE, Faraone SV. When is a ″positive″ association truly a ″positive″
in psychiatric genetics? A commentary based on issues debated
at the World Congress of Psychiatric Genetics, Boston, October
12-18, 2005. Am J Med Genet B Neuropsychiatr Genet 2006;141:
319-22.
[9] Campion D. Stratégies d’étude dans les maladies à hérédité complexe.
In: Thibaut F, editor. Génétique de la schizophrénie. Paris: John Libbey
Eurotext; 2003. p. 55-80.
[10] Keen-Kim D, Mathews CA, Reus V, Lowe T, Herrera LD, Budman CL,
et al. Overrepresentation of rare variants in specific ethnic groups may
confuse interpretation of association analyses. Hum Mol Genet 2006;
15:3324-8.
[11] Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans
of bipolar disorder and schizophrenia. Mol Psychiatry 2002;7:405-11.
[12] Lewis CM, Levinson DF, Wise LH, Delisi LE, Straub RE, Hovatta I,
et al. Genome scan meta-analysis of schizophrenia and bipolar disorder,
part II: schizophrenia. Am J Hum Genet 2003;73:34-48.
[13] Williams NM, O’Donovan MC, Owen MJ. Is the dysbindin gene
(DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull
2005;31:800-5.
[14] Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Pallicio M,
Abderrahim H, et al. Genetic and physiological data implicating the
new human gene G72 and the gene for D-amino acid oxidase in
schizophrenia. Proc Natl Acad Sci USA 2002;99:13675-80.
[15] Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and
bipolar disorder: Review and meta-analysis. Biol Psychiatry 2006;60:
106-14.
[16] Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H,
Shinoda N, et al. Decreased serum levels of D-serine in patients with
schizophrenia. Arch Gen Psychiatry 2003;60:572-6.
[17] Harrison PJ, Law A. Neuregulin 1 and schizophrenia: genetics, gene
expression, and neurobiology. Biol Psychiatry 2006;60:132-40.
[18] Chang-Gyu H, Hoau-Yan W, Dan-Sung C, Konrad T, Raquel EG,
Wade HB, et al. Altered neuregulin 1-erbB4 signaling contributes to
NMDA receptor hypofunction in schizophrenia. Nat Med 2006;12:
824-8.
[19] Craddock N, O’Donovan MC, Owen MJ. Genes for schizophrenia and
bipolar disorder? Implications for psychiatric nosology. Schizophr Bull
2006;32:9-16.
[20] Talkowski M, Chowdari KV, Lewis DA, Nimgahonkar VL. Can RGS4
Polymorphisms be viewed as credible risk factors for schizophrenia?A
critical review of the evidence. Schizophr Bull 2006;32:203-8.
[21] Gogos JA, Gerber DJ. Schizophrenia susceptibility genes: emergence
of positional candidates and future directions. Pharmacol Sci 2006;27:
226-31.
[22] Bonnet-Brilhault F, Thibaut F, Petit M. Données biologiques de la
schizophrénie. EMC (Elsevier Masson SAS, Paris), Psychiatrie,
37-285-A-17, 2001 : 11p.
[23] Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Metaanalysis
of genetic association studies supports a contribution of
common variants to susceptibility to common disease. Nat Genet 2003;
33:177-82.
[24] Thibaut F. L’hypothèse neurodéveloppementale de la schizophrénie.
In: Spadone C, editor. Les schizophrénies. Des avancées théoriques à la
pratique clinique. Paris: édition Pil; 2004. p. 73-91.
[25] Guillin O, Demily C, Thibaut F. Brain-derived neurotrophic factor in
schizophrenia and its relation with dopamine. Int Rev Neurobiol 2007;
78:377-95.
[26] Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH,
Egan MF, et al. Brain-derived neurotrophic factor val66met
polymorphism affects human memory-related hippocampal activity
and predicts memory performance. J Neurosci 2003;23:6690-4.
[27] Thibaut F, Campion D, Laurent C, Bonnet-Brilhault F, Petit M. Mutations
dynamiques de l’ADN, anticipation et schizophrénie. Encephale
1997;23:22-7.
[28] Thibaut F, Martinez M, Petit M, Jay M, Campion D. Further evidence
for anticipation in schizophrenia. Psychiatry Res 1995;59:25-33.
[29] Di Maggio C, Martinez M, Ménard JF, Petit M, Thibaut F. Evidence of
a cohort effect for age at onset of schizophrenia. Am J Psychiatry 2001;
158:489-92.
[30] Petronis A, Kennedy JL. Unstable genes: unstable mind? Am
J Psychiatry 1995;152:164-72.
[31] Husted J, Scutt LE, Bassett AS. Paternal transmission and anticipation
in schizophrenia. Am J Med Genet 1998;81:156-62.
[32] Vincent JB, Kalsi G, KlempanT,TatuchY, Scherrington RP, BreschelT,
et al. No evidence of expansion of CAG or GAA repeats in
schizophrenia families and monozygotic twins. Hum Genet 1998;103:
41-7.
[33] Haaf T, Sirugo G, Kidd K. Chromosomal localization of long
trinucleotide repeats in the human genome by fluorescence in situ
hybridization. Nat Genet 1996;12:183-5.
[34] Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al.
Identification of the spinocerebellar ataxia type 2 gene using a direct
identification of repeat expansion and cloning technique, DIRECT. Nat
Genet 1996;14:277-84.
[35] Bonnet-Brilhault F, Laurent C, Campion D, Thibaut F, Lafargue C,
Charbonnier F, et al. No evidence for involvement of KCNN3
(hSKCa3) potassium channel gene in familial and isolated cases of
schizophrenia. Eur J Hum Genet 1999;7:247-50.
[36] Margolis RL, Stine OC, McInnis MG, Ranen NG, Rubinsztein DC,
Leggo J, et al. cDNA cloning of a human homologue of the C elegans
cell fate-determining gene mab-21: expression, chromosomal
localization and analysis of a highly polymorphic (CAG)n trinucleotide
repeat. Hum Mol Genet 1996;5:607-16.
[37] Thibaut F. Génétique de la schizophrénie. Paris: John Libbey Eurotext;
2003.
[38] Gottesman II, Gould TD. The endophenotype concept in psychiatry:
etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
[39] Houy E, Thibaut F. Données électrophysiologiques dans la schizophrénie
: onde P50 des potentiels évoqués auditifs. EMC (à paraître en
2007).
[40] Faraone SV, Su J, Taylor L, Wilcox M. A novel permutation testing
method implicates sixteen nicotinic acetylcholine receptor genes as risk
factors for smoking in schizophrenia families. Hum Hered 2004;57:
59-68.
[41] Leonard S, Adler LE, Benhammou K, Berger R, Breese CR,
Drebing C, et al. Association of promoter variants in the alpha 7
nicotinic acetylcholine receptor subunit gene with an inhibitory
deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:
1085-96.
[42] Raux G, Bonnet-Brilhault F, Louchart S, Houy E, Gantier R,
Levillain D, et al. The-2 bp deletion in exon 6 of ″alpha 7-like″ nicotinic
receptor subunit gene is a risk factor for the P50 sensory gating deficit.
Mol Psychiatry 2002;7:1006-11.
[43] Houy E, Raux G, Thibaut F, Belmont A, Demily C, Allio G, et al. The
promoter-194 C polymorphism of the nicotinic alpha 7 receptor gene
has a protective effect against the P50 sensory gating deficit. Mol
Psychiatry 2004;9:320-2.
[44] Leonard S, Freedman R. Genetics of chromosome 15q13-q14 in
schizophrenia. Biol Psychiatry 2006;60:115-22.
[45] Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in
schizophrenia. Clin Ther 2005;27(supplA):S25-S37.
[46] Sitskoorn MM, Aleman A, Ebisch S, Appels M, Kahn R. Cognitive
deficits in relatives of patients with schizophrenia: a meta-analysis.
Schizophr Res 2004;71:285-95.
[47] SzökeA, Schurhoff F, Mathieu F, MearyA, Ionescu S, Leboyer M. Test
of executive functions in first-degree relatives of schizophrenic
patients: a meta-analysis. Psychol Med 2005;35:771-82.
[48] Gourion D, Goldberger C, Bourdel MC, Baylé FJ, Millet B, Olié JP,
et al. Neurological soft signs and minor physical anomalies in
schizophrenia: differential transmission within families. Schizophr Res
2003;63:181-7.
[49] Matthysse S, Holzman PS, Gusella JF, Levy DL, Harte CB,
Jorgensen A, et al. Linkage of eye movement dysfunction to chromosome
6p in schizophrenia: additional evidence. Am J Med Gent B
Neuropsychiatr Genet 2004;128:30-6.
10 Psychiatrie